GLP-1 Triple Agonist (RTA)

GLP-1 Triple Agonist (RTA) is a synthetic multi-receptor peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. As an advanced investigational triple-agonist compound (also referenced in research as a triple incretin mimetic), it exhibits one of the most potent profiles studied for metabolic regulation, with clinical trial data showing superior body weight reduction, enhanced energy expenditure, and improved glycemic outcomes compared to single or dual-agonist agents.

Benefits:

• Promotes substantial, sustained weight loss via multi-pathway appetite suppression and increased fat oxidation
• Enhances energy expenditure and metabolic rate through glucagon receptor activation
• Improves insulin sensitivity, glucose homeostasis, and cardiometabolic parameters in research models

Disclaimer: This product is intended for research purposes only and is not approved for human or veterinary use.